UNSPSC 51334305: Thiothixene or tiotixene

This classification denotes an antipsychotic agent with the molecular formula C23H29N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7318FJ13YJ, chemically known as cp-12,252-1 base but generally known as thiothixene, which bears US NIH Compound Identifier 5454. European Medicines Agency schedules Tiotixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11094MIG.

The term TIOTIXENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). World Health Organization schedules thiothixene in its Anatomical Therapeutic Chemical (ATC) Classification. Thiothixene or tiotixene bears US NLM identifiers UMLS ID C0039955 and NCI Concept Code C47752. SMILES: CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.

UNSPSC 51334305 Thiothixene or tiotixene is a Commodity code that nominally covers a specific antipsychotic pharmaceutical, but recent state and local opportunities tagged under this code do not reflect purchases of thiothixene itself. Instead, Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities in multiple states including Oregon; and the Texas Health and Human Services Commission issued an RFI in April 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The mismatch between the code's stated pharmaceutical and the actual solicitations suggests this code shows little relevant recent activity for thiothixene procurement specifically.

Activity in recent months centers on broader pharmaceutical and health-product procurement through state health departments, county health authorities, and cooperative purchasing vehicles rather than on a single active pharmaceutical ingredient. Seminole County's procurement represents county-level demand for emergency and harm-reduction products with quarterly delivery to a community health facility; MMCAP's RFP reflects multi-state cooperative purchasing of generic pharmaceuticals through authorized wholesalers with an effective date of July 1, 2026; and the Texas HHS RFI represents early-stage market intelligence gathering for prescription fulfillment programs. No recent solicitations for thiothixene directly appear in the record, and vendors evaluating this code should verify whether state and local procurement offices are actively purchasing this specific drug formulation or whether the code assignment reflects data-entry error or obsolete tagging.